GlassScriptPhysician profile
Douglas C Semler
NPI 1467403600
$24,016.47
in general payments reported to CMS, 2019-2025
30 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $7,661 · 2021: $1,889 · 2022: $594 · 2023: $1,260 · 2024: $1,281 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,765 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,765.47 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16,563.92 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Janssen Biotech, INC. | $1,697.06 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,477.14 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Abbvie INC. | $542.83 | 2019-2025 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $509.34 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $410.12 | 2023-2024 | Vtama |
| Incyte Corporation | $378.82 | 2022-2025 | Opzelura |
| Pfizer INC. | $360.74 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $286.70 | 2019-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $267.24 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $185.10 | 2019-2025 | |
| Genzyme Corporation | $184.67 | 2019-2025 | |
| Ucb, INC. | $178.86 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $120.38 | 2019-2025 | Olumiant, Ebglyss |
| Almirall LLC | $110.32 | 2019-2024 | Klisyri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $88.63 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $80.14 | 2019 | |
| Leo Pharma INC. | $70.34 | 2019-2025 | Adbry, Spevigo |
| Convatec INC. | $69.22 | 2025 | |
| Celgene Corporation | $68.80 | 2019-2023 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $60.38 | 2019 | |
| Encore Dermatology INC. | $57.95 | 2019-2020 | |
| Botanix Sb INC | $56.92 | 2025 | Sofdra |
| Dermira, INC. | $54.88 | 2019-2020 | |
| Organon LLC | $50.51 | 2025 | Vtama |
| Epi Health, LLC | $23.28 | 2019 | |
| Merck Sharp & Dohme LLC | $18.84 | 2019 | |
| Allergan, INC. | $16.06 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.71 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Semler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.